Combination Flu and COVID-19 Vaccine Prompts Immune Response in Older Adults

A recent study of Moderna’s combination influenze (flu) and COVID-18 vaccine, mRNA-1083, found that it induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all four influenza strains (among those ages 50 to 64 years), the three clinically relevant influenza strains (among those aged 65 years and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.

Study Finds RSV Vaccines Protect Older Adults with 75 Percent Effectiveness

A comprehensive new study published in JAMA Network Open revealed that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged 60 and older, with approximately 75 percent effectiveness against RSV-associated respiratory illness.  In the study, researchers analyzed data from more than 787,000 older adults tested for RSV between October 2023 and April 2024, […]

Grifols Receives $21M to Study Parkinson’s Plasma Samples

Image of blood vials

Grifols has received $21 million from the Michael J. Fox Foundation to fund a pilot study analyzing the company’s repository of longitudinal Parkinson’s disease (PD) plasma samples in hopes of developing an early-warning system for the emergence of PD.

FDA Approves Chikungunya Vaccine

The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.